Table 1:

Clinical characteristics, immunosuppressive treatments and COVID-19 course.

ID	Age (range)	Comorbidities	Immunosuppressive medications in the previous 6 months								Previous Covid vaccine	SARS- CoV2 Anti-S Ab	SARS- CoV2 Anti-N Ab	Days PCR +	Neutropenia (<1.42x103/ml)	Lympho penia (<1.17x103/ml)	Total IgG 610 -1,616 mg/dL	PNA	ICU	O2	Covid Treatments					Covid Outcome
			Fludarabine/ melphalan/ TBI 400cGy	Alemtuzumab	Tacrolimus	MMF	Anti thymocyte globulin	Rituximab	Steroids	Other											RDV	DEXA	Toci	mAb	PAX
1995	60-65	MDS, SCT	Yes	Yes	Yes				Yes	Ruxolitinib	No	No	Yes	28	No	Yes	621	Yes	No	No	Yes	Yes	No	No	No	Discharged home
2646	40-45	AML	Yes							Decitabine Venetoclax	No	No	Yes	32+	No	No	695	Yes	Yes	HFNC	Yes	Yes	No	No	No	Discharged home.
10939	80-85	Kidney Tx			Yes	Yes					No	No	Yes	33@	No	Yes	1072	Yes	Yes	INV	Yes (x2)	Yes	No	No	No	Deceased
11595	66-70	AIHA, MGUS						Yes	Yes	Ibrutinib	No	No	No	38	Yes	Yes	217	Yes	No	HFNC	Yes	Yes	No	No	No	Deceased
12105	66-70	T-PLL, SCT	Yes	Yes	Yes	Yes	Yes	Yes	Yes	PLEX	No	No	No	58@	Yes	Yes	232	Yes	Yes	INV	Yes	Yes	Yes	Casi/indi	No	Deceased
14675	66-70	CLL						Yes	Yes	Polartuzmab Etoposide Doxorubicin CFX	Yes	No	No	66	No	Yes	578	Yes	No	No	Yes	No	No	Tixa/Cilga	Yes	Discharged home
16624	60-65	mantle cell lymphoma, SCT						Yes	Yes		Yes	Yes	No	42	No	Yes	418	Yes	No	NC	Yes	Yes	No	No	No	Discharged home
16902	70-75	MDS, SCT	Yes	Yes	Yes			Yes			No	Yes	No	50@	Yes	Yes	484	Yes	No	INV	Yes (x2)	Yes	Yes	Sotrovimab	No	Deceased
16915	20-25	AML, SCT	Yes		Yes	Yes	Yes	Yes			No	No	No	63	No	No	563	Yes	No	No	Yes	No	No	Tixa/Cilga	No	Discharged home
17062	26-30	BMFS, SCT	Yes		Yes	Yes	Yes			Fludarabine, CFX	No	Yes	Yes	72	Yes	Yes	270	Yes	Yes	NC	Yes	Yes	No	No	No	Deceased
17320	70-75	mantle cell lymphoma								Fludarabine, CFX CAR-T cells	Yes	No	No	34	Yes	Yes	447	Yes	No	No	Yes	Yes	No	No	No	Discharged home
17386	60-65	DLBCL						Yes	Yes	CHOP	No	Yes	No	157	No	Yes	810	Yes	No	NC	Yes (x4)	Yes	Yes	Sotrovimab	No	Discharged home
17423	60-65	B-ALL, SCT, GVHD	Yes		Yes	Yes	Yes			Ruxolitinib	Yes	Yes	No	190	No	Yes	797	Yes	No	NC	Yes	Yes	No	No	No	Deceased
18323	36-70	AML, SCT	Yes		Yes	Yes	Yes			Desatinib,	No	No	No	131	No	Yes	926	Yes	No	No	Yes	No	No	Tixa/Cilga Bebtel	Yes	Discharged home
17072	60-65	MM							Yes	Elranatam	Yes	No	No	81	No	Yes	441	Yes	Yes	IMV	Yes (x3)	Yes	No	No	Yes	Deceased

Abbreviations. AIHA: Autoimmune hemolytic anemia; ALL: acute lymphoid leukemia; AML: acute myeloid leukemia; aSCT: autologous stem cell transplant; BMFS: Bone marrow failure syndrome; CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone; CLL: chronic Lymphoid Leukemia; DLBCL: diffuse large B cell Lymphoma; GVHD graft versus host disease; MDS: myelodysplastic syndrome; MGUS: monoclonal gammopathy of undetermined significance, MM multiple myeloma; PLEX: plasma exchange; SCT stem cell transplant; TBI: total body irradiation; T-PLL: T-cell prolymphocytic leukemia; Tx: transplant. CFX: cyclophosphamide; Bebtel: Bebtelovimab; Casi/indi: casirivimab and imdevimab; DEXA: dexamethasone; HFNC: high-flow nasal cannula. ICU: intensive care unit; IMV: invasive mechanical ventilation; NC: nasal cannula; NIV: non-invasive ventilation; O2: oxygen requirements; PAX: nirmatrelvir/ritonavir (Paxlovid^™); PNA pneumonia; RDV: remdesivir; Toci: Tociluzimab; Tixa/Cilga: Tixagevimab/Cilgavimab (Evusheld^™). @ indicates that the patient died while SARS-CoV2 positive; + indicates that the patient died in the following month after hospitalization without retesting for SARS-CoV2.